tiprankstipranks
Alterity Therapeutics Reveals Positive MSA Trial Data
Company Announcements

Alterity Therapeutics Reveals Positive MSA Trial Data

Alterity Therapeutics Ltd. (AU:ATH) has released an update.

Don't Miss our Black Friday Offers:

Alterity Therapeutics has reported promising interim data from its Phase 2 clinical trials of ATH434, showing potential to modify disease progression in Multiple System Atrophy (MSA). With a cash balance of A$9.28 million, the company remains optimistic as it anticipates releasing topline results in 2025. Additionally, Alterity has strengthened its leadership by appointing Abby Macnish Niven as CFO.

For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyAlterity Therapeutics appoints Abby Macnish Niven as secretary
TipRanks Australian Auto-Generated NewsdeskAlterity Therapeutics Appoints New Company Secretary
TheFlyAlterity Therapeutics announces presentation on bioMUSE study
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App